Study title:
Clinical trial (phase II) to evaluate the efficacy of MVANP+M1 in a human H3N2 influenza challenge model.
Long title:
Clinical trial (phase II) to evaluate the efficacy of MVANP+M1 in a human H3N2 influenza challenge model.
Date receipt dossier:
14 jan 2019
EU record number:
FLU10
EudraCT number:
2018-004015-49
Pharmaceutical study code:
MVA-NP+M1
Company / Sponsor:
Vaccitech Limited
Phase:
II
Treated organism:
Humans
Indication category:
Infectious disease
Disease:
Influenza virus infection (seasonal flu)
Therapeutic approach:
Prevention
Genetic modification:
Vaccinia virus Ankara strain expressing nucleoprotein (NP) and Matrix protein (M1) from influenza A H3N2 virus
Method of transfer of nucleic acid of interest:
Not applicable
Administered biological material:
Recombinant vaccinia virus (MVA) expressing nucleoprotein (NP) and Matrix protein (M1) from influenza A H3N2 virus
Route of administration:
Intramuscular
Locations in Belgium:
SGS Belgium NV
Type of procedure:
Contained use only
Current status:
Authorized